A biomarker for CV disease in RA? Anti-CXCR3 antibodies asso w/ atherosclerosis Confirmed in a validation cohort Adding Ab profile to the mSCORE increases AUC from 0.6 to 0.9 Sens from 30 to 69% How does it compare with other ways of detecting atherosclerosis? #POS0899 https://t.co/O7bsLrVyzo

• https://x.com/AurelieRheumo/status/2062922909606175060/photo/1
• https://x.com/AurelieRheumo/status/2062922909606175060/photo/1

How to treat #RA-#ILD Similar to #IPF Occurs older men esp Smoking risk Vaccines Etc Philippe Dieude #HOT #EULAR2026 @RheumNow https://t.co/F4h9daSLhF

• https://x.com/Janetbirdope/status/2062914666938896727/photo/1

Which b/tsDMARDs are effective in #axSpA? Stratified by extramusculoskeletal manifestations Check out the latest update of the treatment heatmap 🔥 By Astrid van Tubergen At axial and peripheral SpA at a crossroads session #EULAR2026 @RheumNow https://t.co/uTxEJqbDBm

• https://x.com/Nellziade/status/2062912494360813829/photo/1

Controversial #Rheumatoid #arthritis disease activity May not affect #ILD BUT affects #mortality level evidence +/- PHillippe Dieude said #Rx from RCTs #IS Ex #rituximab #antifibrotics #nintedanib #nerandomilast HOw to Treat RA-ILD June 5 #EULAR2026 @RheumNow @eular_ARD https://t.co/R60nX6XzL8

• https://x.com/Janetbirdope/status/2062912379818545502/photo/1
• https://x.com/Janetbirdope/status/2062912379818545502/photo/1
• https://x.com/Janetbirdope/status/2062912379818545502/photo/1

Which b/tsDMARDs are NOT effective in #axSpA? Check out the latest update of the treatment heatmap 🔥 By Astrid van Tubergen At axial and peripheral SpA at a crossroads session #EULAR2026 @RheumNow https://t.co/hqfLAYeri3

• https://x.com/Nellziade/status/2062911970446061888/photo/1

Key messages in the tx of ax/p-SpA: >csDMARDs only effective in pSpA >consider individualized treatment for bDMARDs and JAKis >Cycling TNFi equally effective to switching @RheumNow #EULAR2026 https://t.co/oeO3BxmYYo

• https://x.com/RHEUMarampa/status/2062911936103100779/photo/1

JAK Safety Debate Continues: Stronger VTE signal, less clear cancer signal Few topics in rheumatology have reshaped prescribing behaviour as dramatically as the safety concerns surrounding JAK inhibitors following ORAL Surveillance and the subsequent FDA and EMA warnings. https://t.co/mvTRRL7srA

Which b/tsDMARDs are effective in #axSpA? Check out the latest update of the treatment heatmap 🔥 By Astrid van Tubergen At axial and peripheral SpA at a crossroads session #EULAR2026 @RheumNow https://t.co/8mj24lAOTk

• https://x.com/Nellziade/status/2062911645907591648/photo/1

What b/ts DMARDs are effective and not effective in axSpA? Prof. Astrid van Tubergen presents this very informative summary slide summarizing treatment in axSpA. @RheumNow #EULAR2026 https://t.co/5udGPB1Hrr

• https://x.com/RHEUMarampa/status/2062910496693510239/photo/1
• https://x.com/RHEUMarampa/status/2062910496693510239/photo/1

What is the @Official_ASAS recommended instrument for evaluating peripheral disease activity in axial and peripheral spondyloarthritis? 👉 DAPSA44 ✔️Good construct validity ✔️ High discriminatory capacity From the ASAS-Sparadise study #EULAR2026 @RheumNow https://t.co/Jbdvpn95jE

• https://x.com/Nellziade/status/2062908825376592209/photo/1

#immune #reset may be ‘asking the earth’ and we may need to consider #immune #dimming ➡️esp if multi drug failure already By Hector Chinoy #WIN #IIM June5 Excellent #CAR-T review should re think of Total immune reset in many #SARD PTS is unlikely EULAR2026 @RheumNow https://t.co/eqKzxzqa0z

• https://x.com/Janetbirdope/status/2062905361888096685/photo/1
• https://x.com/Janetbirdope/status/2062905361888096685/photo/1
• https://x.com/Janetbirdope/status/2062905361888096685/photo/1
• https://x.com/Janetbirdope/status/2062905361888096685/photo/1

Using AI to integrate EHR, SDOH , psychological data - can help finding psychosocial risk factors. Complex cases can be diagnosed using solutions (iceberg health) like this. #EULAR2026 @rheumnow https://t.co/t4keRbpkrx

• https://x.com/bella_mehta/status/2062902410171781352/photo/1
• https://x.com/bella_mehta/status/2062902410171781352/photo/1

Not just ticking boxes! Prof. Rudwaleit on the revised 2025 ASAS/SPARTAN criteria for axSpA What’s new? Providing a stem so criteria will be applied only if w/SpA dx, not just imaging MRI:active inflamm + structural lesions Some SpA features omitted @RheumNow #EULAR2026 https://t.co/NCV0EFvjYa

• https://x.com/RHEUMarampa/status/2062900936402485307/photo/1
• https://x.com/RHEUMarampa/status/2062900936402485307/photo/1
• https://x.com/RHEUMarampa/status/2062900936402485307/photo/1
• https://x.com/RHEUMarampa/status/2062900936402485307/photo/1

Can we have an effective, comprehensive score for #SLE #arthritis? #SLEDAI has a problem SJC>2 scores dames as ex #SJC=12 Meet #LAMBDA An attempt to improve a true positive #MSK OUTCOME in #lupus Needs validation esp in pts over time #EULAR2026 @RheumNow #POS1072 @eular_org https://t.co/fr0xuVqFnM

• https://x.com/Janetbirdope/status/2062877860562346175/photo/1

Large French nationwide cohort (n=56,591 SpA patients) showed that >6 months/year of targeted therapy exposure was associated with reduced overall cancer risk (wHR 0.86), especially for haematological malignancies (wHR 0.65). Reassuring long-term safety signal. Abstr OP0238